Upgrade to SI Premium - Free Trial

Revolution Medicines (RVMD)

210.02 -0.85 (0.40%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/11/26)

Latest Headlines

Revolution (RVMD) PT Raised to $275 at Needham August 31, 2026 7:19 AM - StreetInsider Revolution (RVMD) PT Raised to $265 at UBS as Daraxonrasib Pricing Announced August 28, 2026 7:16 AM - StreetInsider Revolution (RVMD) PT Raised to $275 at Guggenheim August 28, 2026 7:12 AM - StreetInsider Revolution (RVMD) PT Raised to $246 at JPMorgan August 27, 2026 8:30 AM - StreetInsider Revolution (RVMD) PT Raised to $251 at RBC Capital August 27, 2026 7:55 AM - StreetInsider Revolution (RVMD) PT Raised to $280 at H.C. Wainwright August 27, 2026 7:00 AM - StreetInsider Revolution (RVMD) PT Raised to $239 at Truist Securities August 27, 2026 6:59 AM - StreetInsider Revolution (RVMD) PT Raised to $260 at Oppenheimer August 26, 2026 5:01 PM - StreetInsider Bloomberg 500 (B500) Index Adds Ten Securities Following September Reconstitution August 26, 2026 4:33 PM - PR NewsWire Revolution Medicines prices RASONQUE at $39,800 per month August 26, 2026 1:54 PM - StreetInsider Form 8-K Revolution Medicines, For: Aug 26 August 26, 2026 1:34 PM - SEC Filing FDA approves Revolution Medicines' daraxonrasib for pancreatic cancer August 26, 2026 12:59 PM - StreetInsider U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer August 26, 2026 12:59 PM - Globe NewsWire FDA approves Revolution Medicines pancreatic cancer drug Rasonque August 26, 2026 10:43 AM - StreetInsider Form 4 Revolution Medicines, For: Aug 21 Filed by: Cislini Jeff August 25, 2026 4:07 PM - SEC Filing Form 4 Revolution Medicines, For: Aug 21 Filed by: GOLDSMITH MARK A August 25, 2026 4:06 PM - SEC Filing TD Cowen Assumes Revolution (RVMD) at Buy August 22, 2026 7:54 AM - StreetInsider Form 144 Revolution Medicines, Filed by: GOLDSMITH MARK A August 21, 2026 4:38 PM - SEC Filing Form 144 Revolution Medicines, Filed by: GOLDSMITH MARK A August 21, 2026 4:38 PM - SEC Filing Form 144 Revolution Medicines, Filed by: GOLDSMITH MARK A August 21, 2026 4:38 PM - SEC Filing Form 144 Revolution Medicines, Filed by: Cislini Jeff August 21, 2026 4:34 PM - SEC Filing Revolution (RVMD) PT Raised to $179 at Bernstein SocGen Group August 21, 2026 8:46 AM - StreetInsider Form SCHEDULE 13G Revolution Medicines, Filed by: BAKER BROS. ADVISORS LP August 14, 2026 4:03 PM - SEC Filing Form SCHEDULE 13G/A Revolution Medicines, Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C. August 13, 2026 5:20 PM - SEC Filing Form SCHEDULE 13G Revolution Medicines, Filed by: Janus Henderson Group Ltd. August 13, 2026 12:31 PM - SEC Filing Propanc Biopharma plans Phase 1b trial for cancer drug PRP August 12, 2026 8:32 AM - StreetInsider Revolution (RVMD) PT Raised to $231 at Truist Securities August 11, 2026 7:07 AM - StreetInsider TD Cowen: 'Revolution (RVMD) Firing On All Cylinders' August 10, 2026 9:09 AM - StreetInsider BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration August 10, 2026 6:00 AM - BizWire Revolution (RVMD) PT Raised to $230 at Oppenheimer August 6, 2026 8:37 AM - StreetInsider Revolution (RVMD) PT Raised to $240 at Needham August 6, 2026 7:14 AM - StreetInsider Revolution (RVMD) PT Raised to $203 at RBC Capital August 6, 2026 6:58 AM - StreetInsider Revolution (RVMD) PT Raised to $240 at Guggenheim August 6, 2026 6:45 AM - StreetInsider Revolution (RVMD) PT Raised to $240 at Wells Fargo August 6, 2026 6:38 AM - StreetInsider Revolution Medicines, Inc. (RVMD) Misses Q2 EPS by 110c August 5, 2026 4:54 PM - StreetInsider Form 10-Q Revolution Medicines, For: Jun 30 August 5, 2026 4:14 PM - SEC Filing Revolution Medicines, Inc. (RVMD) Misses Q2 EPS by 110c August 5, 2026 4:14 PM - StreetInsider Form 8-K Revolution Medicines, For: Aug 05 August 5, 2026 4:06 PM - SEC Filing Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress August 5, 2026 4:02 PM - Globe NewsWire Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026 July 29, 2026 4:05 PM - Globe NewsWire Form SCHEDULE 13G Revolution Medicines, Filed by: BlackRock, Inc. July 29, 2026 3:22 PM - SEC Filing Revolution (RVMD) PT Raised to $192.10 at Wedbush July 23, 2026 8:27 AM - StreetInsider FDA accepts Revolution Medicines NDA for daraxonrasib in pancreatic cancer July 22, 2026 4:05 PM - StreetInsider Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer July 22, 2026 4:05 PM - Globe NewsWire Truist Securities Reiterates Buy Rating on Revolution (RVMD) July 10, 2026 9:10 AM - StreetInsider Revolution (RVMD) PT Raised to $235 at Guggenheim July 9, 2026 7:09 AM - StreetInsider EMA begins phased review of Revolution Medicines' daraxonrasib July 7, 2026 9:24 AM - StreetInsider European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process July 7, 2026 9:24 AM - Globe NewsWire Revolution (RVMD) PT Raised to $220 at UBS July 6, 2026 9:23 AM - StreetInsider Revolution (RVMD) PT Raised to $215 at Mizuho July 6, 2026 8:00 AM - StreetInsider Revolution (RVMD) PT Raised to $181 at Wedbush July 2, 2026 12:09 PM - StreetInsider Revolution Medicines reports Phase 1/2 data for zoldonrasib in pancreatic cancer July 2, 2026 8:01 AM - StreetInsider Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026  July 2, 2026 8:00 AM - Globe NewsWire Form 4 Revolution Medicines, For: Jun 29 Filed by: Patel Sushil July 1, 2026 6:25 PM - SEC Filing Revolution (RVMD) PT Raised to $210 at Truist Securities June 30, 2026 6:54 AM - StreetInsider Form 144 Revolution Medicines, Filed by: Patel Sushil June 29, 2026 4:45 PM - SEC Filing Revolution (RVMD) PT Raised to $235 at Needham June 29, 2026 8:18 AM - StreetInsider Form 4 Revolution Medicines, For: Jun 24 Filed by: Anders Jack June 26, 2026 4:10 PM - SEC Filing Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 June 24, 2026 7:31 PM - Globe NewsWire Form 144 Revolution Medicines, Filed by: Anders Jack June 24, 2026 4:36 PM - SEC Filing Form 4 Revolution Medicines, For: Jun 18 Filed by: Kim Lorence H. June 23, 2026 5:57 PM - SEC Filing Form 4 Revolution Medicines, For: Jun 18 Filed by: Borisy Alexis June 23, 2026 5:52 PM - SEC Filing Form 4 Revolution Medicines, For: Jun 18 Filed by: ANDERSON ELIZABETH M June 23, 2026 5:46 PM - SEC Filing Form 4 Revolution Medicines, For: Jun 18 Filed by: Horning Sandra June 23, 2026 5:45 PM - SEC Filing Form 4 Revolution Medicines, For: Jun 18 Filed by: Clyburn Frank June 23, 2026 5:44 PM - SEC Filing Form 4 Revolution Medicines, For: Jun 18 Filed by: Patel Sushil June 23, 2026 5:44 PM - SEC Filing Form 4 Revolution Medicines, For: Jun 18 Filed by: Borellini Flavia June 23, 2026 5:42 PM - SEC Filing Revolution Medicines starts Phase 3 trial of zoldonrasib for pancreatic cancer June 23, 2026 8:00 AM - StreetInsider Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Met June 23, 2026 8:00 AM - Globe NewsWire RBC Capital Reiterates Outperform Rating on Revolution (RVMD) June 22, 2026 9:41 AM - StreetInsider Revolution Medicines R&D chief to step down ahead of 2027 retirement June 22, 2026 8:01 AM - StreetInsider Form 8-K Revolution Medicines, For: Jun 18 June 22, 2026 8:00 AM - SEC Filing Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D. June 22, 2026 8:00 AM - Globe NewsWire Form 4 Revolution Medicines, For: Jun 16 Filed by: Mancini Anthony June 18, 2026 4:11 PM - SEC Filing Form 4 Revolution Medicines, For: Jun 16 Filed by: GOLDSMITH MARK A June 18, 2026 4:11 PM - SEC Filing Form 4 Revolution Medicines, For: Jun 16 Filed by: Cislini Jeff June 18, 2026 4:11 PM - SEC Filing Form 4 Revolution Medicines, For: Jun 16 Filed by: Anders Jack June 18, 2026 4:10 PM - SEC Filing Form 4 Revolution Medicines, For: Jun 16 Filed by: Kelsey Stephen Michael June 18, 2026 4:10 PM - SEC Filing Form 4 Revolution Medicines, For: Jun 15 Filed by: Horn Margaret A June 17, 2026 7:52 PM - SEC Filing Form 144 Revolution Medicines, Filed by: GOLDSMITH MARK A June 15, 2026 6:30 PM - SEC Filing Form 144 Revolution Medicines, Filed by: Cislini Jeff June 15, 2026 6:23 PM - SEC Filing Form 144 Revolution Medicines, Filed by: Anders Jack June 15, 2026 6:16 PM - SEC Filing Form 144 Revolution Medicines, Filed by: Mancini Anthony June 15, 2026 6:07 PM - SEC Filing Form 144 Revolution Medicines, Filed by: Kelsey Stephen Michael June 15, 2026 6:00 PM - SEC Filing Form 144 Revolution Medicines, Filed by: Horn Margaret A June 15, 2026 5:52 PM - SEC Filing Form 144 Revolution Medicines, Filed by: Horn Margaret A June 15, 2026 5:00 PM - SEC Filing Form 4 Revolution Medicines, For: Jun 11 Filed by: Horn Margaret A June 15, 2026 4:06 PM - SEC Filing Form 144 Revolution Medicines, Filed by: Horn Margaret A June 11, 2026 4:28 PM - SEC Filing UBS Reiterates Buy Rating on Revolution (RVMD) Following Trial Data Release June 9, 2026 9:24 AM - StreetInsider Revolution (RVMD) trading up 1%, RBC says that's about what they expected it to trade June 8, 2026 9:38 AM - StreetInsider Full Article List